验证用于评估无症状肾移植候选者的心肌灌注显像临床路径
该回顾性队列研究纳入581例连续肾移植受者,其中401例移植前接受放射性核素心肌灌注显像(MPI),90例接受冠状动脉造影。结果显示,AHA/ACCF风险因素≥3个的无症状肾移植候选者心脏风险增加,应考虑无创冠状动脉疾病监测;中等风险(3-4个因素)患者从移植前MPI中获益最大,用于定义长期主要不良心脏事件风险。
要点
- AHA/ACCF风险因素≥3个的无症状肾移植候选者心脏风险增加,应考虑无创冠状动脉疾病监测。
- 风险因素总和对于阻塞性冠状动脉疾病、术后30天MACE和长期MACE的判别能力分别为AUC 0.70、0.60和0.63。
- 中等风险(3-4个风险因素)患者从移植前MPI中获益最大,用于定义长期MACE风险。
核心结论
- AHA/ACCF风险因素≥3个的无症状肾移植候选者心脏风险增加,应考虑无创冠状动脉疾病监测。
- 中等风险(3-4个因素)患者从移植前MPI中获益最大,用于定义长期MACE风险。
研究设计与样本
- 回顾性随访581例连续肾移植受者,其中401例移植前接受放射性核素心肌灌注显像(MPI),90例移植前接受冠状动脉造影。
- 计算移植前AHA/ACCF风险因素总和(年龄>60岁、高血压、糖尿病、心血管疾病、血脂异常、吸烟、透析>1年、左心室肥厚)。
- MPI扫描由「盲法」阅片者分析;移植后随访平均3.7±2.3年,观察主要不良心脏事件(MACE),定义为心脏死亡或非致命性心肌梗死。
主要发现
- 风险因素总和与阻塞性血管造影冠状动脉疾病相关(AUC 0.70;P=0.004)。
- 风险因素总和与术后30天MACE相关(AUC 0.60;P=0.036)。
- 风险因素总和与长期MACE相关(AUC 0.63;P<0.001)。
- MPI对阻塞性冠状动脉疾病提供增量预测价值(P=0.02),对长期MACE提供增量预测价值(P=0.04),但对术后MACE未提供增量预测价值(P=0.56)。
- MPI对中等风险(3-4个风险因素)患者的长期MACE预测最佳。
关键数值与推荐
- AHA/ACCF风险因素≥3个为识别风险患者的最佳阈值。
- MPI对阻塞性冠状动脉疾病增量预测价值P=0.02,对长期MACE增量预测价值P=0.04,对术后MACE增量预测价值P=0.56。
临床怎么用
- AHA/ACCF风险因素≥3个的无症状肾移植候选者心脏风险增加,应考虑无创冠状动脉疾病监测。
- 中等风险(3-4个因素)患者从移植前MPI中获益最大,用于定义长期MACE风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An AHA/ACCF scientific statement proposed 8 risk factors to assess the need for noninvasive coronary artery disease (CAD) surveillance in asymptomatic patients undergoing evaluation for kidney transplantation. The clinical application of these risk factors and the role of noninvasive testing in this context have not been defined. METHODS AND RESULTS: We retrospectively followed a cohort of 581 consecutive kidney transplant recipients of whom 401 had pre-transplant radionuclide myocardial perfusion imaging (MPI) and 90 had pre-transplant coronary angiography. The sum of pre-transplant AHA/ACCF risk factors (age >60 years, hypertension, diabetes, cardiovascular disease, dyslipidemia, smoking, dialysis >1 year, left ventricular hypertrophy) was calculated. MPI scans were analyzed by a "blinded" reader. Patients were followed for a mean of 3.7 ± 2.3 years post-transplant for major adverse cardiac events (MACE), defined as cardiac death or non-fatal myocardial infarction. The sum of risk factors was associated with modest discriminatory capacity for obstructive angiographic CAD (area under the curve [AUC], 0.70; P = 0.004), 30-day post-operative MACE (AUC, 0.60; P = 0.036), and long-term MACE (AUC, 0.63; P < 0.001). A threshold of ≥3 risk factors was optimal for identifying patients at risk. MPI provided incremental predictive value for obstructive CAD (P = 0.02) and long-term MACE (P = 0.04) but not post-operative MACE (P = 0.56). MPI was best predictive of long-term MACE in intermediate risk (3-4 risk factors) patients. CONCLUSIONS: Asymptomatic kidney transplant candidates with ≥3 AHA/ACCF risk factors are at increased cardiac risk, and should be considered for noninvasive CAD surveillance. Intermediate risk patients (3-4 factors) benefit the most from pre-transplant MPI to define long-term MACE risk.
引用
- Doukky R, Fughhi I, Campagnoli T, et al. Validation of a clinical pathway to assess asymptomatic renal transplant candidates using myocardial perfusion imaging. J Nucl Cardiol. 2017. PMID: 28484986. doi:10.1007/s12350-017-0901-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。